WO2000059493A3 - Improved dialysis solutions and methods - Google Patents

Improved dialysis solutions and methods Download PDF

Info

Publication number
WO2000059493A3
WO2000059493A3 PCT/US2000/009241 US0009241W WO0059493A3 WO 2000059493 A3 WO2000059493 A3 WO 2000059493A3 US 0009241 W US0009241 W US 0009241W WO 0059493 A3 WO0059493 A3 WO 0059493A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
dialysis solutions
improved dialysis
dialysis
improved
Prior art date
Application number
PCT/US2000/009241
Other languages
French (fr)
Other versions
WO2000059493A2 (en
Inventor
Raja Khalifah
Billy Hudson
Original Assignee
Kansas University Medical Ct
Raja Khalifah
Billy Hudson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kansas University Medical Ct, Raja Khalifah, Billy Hudson filed Critical Kansas University Medical Ct
Priority to EP00920205A priority Critical patent/EP1165079A2/en
Priority to CA002360311A priority patent/CA2360311C/en
Priority to AU40783/00A priority patent/AU4078300A/en
Publication of WO2000059493A2 publication Critical patent/WO2000059493A2/en
Publication of WO2000059493A3 publication Critical patent/WO2000059493A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides improved dialysis compositions and methods for dialysis comprising utilizing the disclosed AGE inhibitors, together with methods to reduce dialysis-related complications and disorders.
PCT/US2000/009241 1999-04-06 2000-04-06 Improved dialysis solutions and methods WO2000059493A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00920205A EP1165079A2 (en) 1999-04-06 2000-04-06 Improved dialysis solutions and methods
CA002360311A CA2360311C (en) 1999-04-06 2000-04-06 Improved dialysis solutions and methods
AU40783/00A AU4078300A (en) 1999-04-06 2000-04-06 Improved dialysis solutions and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12790699P 1999-04-06 1999-04-06
US60/127,906 1999-04-06

Publications (2)

Publication Number Publication Date
WO2000059493A2 WO2000059493A2 (en) 2000-10-12
WO2000059493A3 true WO2000059493A3 (en) 2001-02-01

Family

ID=22432569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009241 WO2000059493A2 (en) 1999-04-06 2000-04-06 Improved dialysis solutions and methods

Country Status (4)

Country Link
EP (1) EP1165079A2 (en)
AU (1) AU4078300A (en)
CA (1) CA2360311C (en)
WO (1) WO2000059493A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002237667A1 (en) 2000-11-20 2002-05-27 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474874A1 (en) * 1990-02-19 1992-03-18 Senju Pharmaceutical Co., Ltd. Maillard Reaction inhibitor compositions
WO1997009981A1 (en) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO1999007419A1 (en) * 1997-08-07 1999-02-18 Ajay Gupta Dialysis solutions containing water soluble vitamins and nutrients
WO2000010606A1 (en) * 1998-08-24 2000-03-02 Kurokawa, Kiyoshi Drugs for relieving carbonyl stress and peritoneal dialysates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474874A1 (en) * 1990-02-19 1992-03-18 Senju Pharmaceutical Co., Ltd. Maillard Reaction inhibitor compositions
WO1997009981A1 (en) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO1999007419A1 (en) * 1997-08-07 1999-02-18 Ajay Gupta Dialysis solutions containing water soluble vitamins and nutrients
WO2000010606A1 (en) * 1998-08-24 2000-03-02 Kurokawa, Kiyoshi Drugs for relieving carbonyl stress and peritoneal dialysates

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOOTH A A ET AL: "THIAMINE PYROPHOSPHATE AND PYRIDOXAMINE INHIBIT THE FORMATION OF ANTIGENIC ADVANCED GLYCATION END-PRODUCTS: COMPARISON WITH AMINOGUANIDINE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 220, no. 1, 1996, pages 113 - 119, XP002024845, ISSN: 0006-291X *
DATABASE WPI Week 200031, Derwent World Patents Index; AN 2000-237551, XP002153810, MIYATA TOSHIO: "Drugs for relieving carbonyl stress and peritoneal dialysates" *
HOU FAN FAN ET AL: "Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 9, no. 2, February 1998 (1998-02-01), pages 277 - 283, XP000965311, ISSN: 1046-6673 *
LAMB, E.J.; CATTELL W.R.; DAWNEY A.B.: "In vitro formation of advanced glycation end products in peritoneal dialysis fluids.", KIDNEY INTERNATIONAL, vol. 47, no. 6, 1995, pages 1768 - 1774, XP000964894 *
MUNCH G ET AL: "Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA", EUROPEAN JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY,DE,WALTER DE GRUYTER, BERLIN, vol. 35, no. 9, September 1997 (1997-09-01), pages 669 - 677, XP002116870, ISSN: 0939-4974 *
NAKAYAMA MASAAKI ET AL: "Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.", KIDNEY INTERNATIONAL, vol. 51, no. 1, 1997, pages 182 - 186, XP000965140, ISSN: 0085-2538 *
UEDA YASUHIKO ET AL: "2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) inhibits the glycoxidation reaction in glucose based peritoneal dialysis fluid.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. PROGRAM AND ABSTR. ISSUE, 1999, 32nd Annual Meeting of the American Society of Nephrology;Miami Beach, Florida, USA; November 1-8, 1999, pages 324A, XP000964884, ISSN: 1046-6673 *

Also Published As

Publication number Publication date
AU4078300A (en) 2000-10-23
CA2360311C (en) 2003-03-18
CA2360311A1 (en) 2000-10-12
WO2000059493A2 (en) 2000-10-12
EP1165079A2 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2004029207A3 (en) Optimized fc variants and methods for their generation
AU2001259795A1 (en) Technique for securely conducting online transactions
MXPA03007983A (en) Process for the preparation of middle distillates.
WO2001079461A3 (en) Polypeptides having haloperoxidase activity
AU2002210991A1 (en) Novel glucose dehydrogenase and process for producing the dehydrogenase
WO2001046830A8 (en) Business transactions using the internet
AU2002337047A1 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
AP2003002925A0 (en) Tobacco biomas utilization.
AU2002234143A1 (en) Identity insurance transaction method
WO2002102586A3 (en) Cellulose-polymer composites and methods for manufacturing same
WO2002036106A3 (en) Novel medicament compositions based on anticholinergics and corticosteroids
AU2001276295A1 (en) Electric component, method for the production thereof, and its use
AUPR969501A0 (en) Forfaiting transactions
WO2001040242A3 (en) 6-o-methylerythromycin a crystal form iii
AU2002345758A1 (en) Renewable, carbohydrate based co2-philes
AU2000266451A1 (en) Toughened, high-modulus polyacetals
AU6594401A (en) 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
AU2002223963A1 (en) Transaction certification
WO2000053841A3 (en) Unsupported flat linoleum structure and method of producing same
AU2003241785A1 (en) Intravenous composition, process for producing the same and preparation thereof
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
WO2000059493A3 (en) Improved dialysis solutions and methods
ZA200002546B (en) Sorbate-preserved compositions, method for the manufacture thereof and their use.
WO2004075028A3 (en) Systems and methods for variable rebate and incentive programs
WO2003020767A3 (en) Antibodies against caspase-8, their preparation and use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2360311

Country of ref document: CA

Ref country code: CA

Ref document number: 2360311

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000920205

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920205

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000920205

Country of ref document: EP